Myllia Biotechnology

Myllia Biotechnology SAB member Luke Gilbert publishes landmark paper in Nature Methods, together with Hani Goodarzi and team: https://lnkd.in/e7ygr5s5 The paper introduces a novel computation tool called "SwitchSeeker" that enables the discovery of RNA structural switches. The authors applied the tool to human cells and found 245 putative RNA switches. One of these, a previously unknown RNA switch in the 3ʹ untranslated region of the ROR, was validated in great detail. Furthermore, the authors used genome-scale CRISPR screens to identify trans factors that regulate gene expression through this RNA structural switch. Congrats to all authors!

Exciting times ahead at #BayOConnect2024 hosted by BioM Biotech Cluster Development GmbH in Munich! Myllia Biotechnology is joining the event today and tomorrow, and Thomas Moser is looking forward to lots of discussions about the transformative potential of AI models in revolutionizing drug discovery. Would you like to explore how large-scale CROP-Seq screening can advance drug target discovery? If yes, don't miss to have a chat on site!   #TeamMyllia #CRISPR #CROPseq #AIDrugDiscovery Learn more here: https://myllia.com/

🔊 Job alert! - We are #hiring a Lab Associate/Lab Scientist at Myllia Biotechnology in Vienna, Austria! If you are fascinated about functional genomics and primary immune cell biology, please send your application to Dr. Tilmann Buerckstuemmer (jobs@myllia.com). We look forward to receiving your application! https://lnkd.in/d2NnZRQw #TeamMyllia #CRISPR #screening #job

Last week, Myllia Biotechnology hosted their annual Scientific Advisory Board (SAB) meeting in Prein an der Rax. Myllia SAB members Christoph Bock, Luke Gilbert and Rodrigo Santos joined this meeting and spent time with the entire group. Myllia CSO Tilmann Burckstummer commented: "We spent two days reviewing and discussing the cutting-edge science that happens at Myllia. Thanks a lot to the Myllia SAB for their valuable input and feedback." #mylliabio

Hello San Diego! Myllia Biotechnology is currently attending #BIO2024 and we look forward to lots of great discussions with new collaborators interested in #functional #genomics and high-content #CRISPR screens for target discovery. If you like, reach out to our colleague Henrik Schmidt directly on site! #TeamMyllia www.myllia.com

Meet Myllia Biotechnology at this year's Biotechnology Innovation Organization International Convention in San Diego, CA from June 3-6, 2024! We look forward to connecting on site, and please reach out to Henrik Schmidt via the partnering platform if you'd like to discuss #CRISPR screens for target discovery.   #BIO2024 #TeamMyllia Learn more here: https://lnkd.in/ekYZCRKk

Thrilled to announce that Myllia Biotechnology is gearing up for #BIO2024 in San Diego! We're looking forward to connecting with industry experts and potential collaborators at this year's #biopharma #partnering event hosted by the San Diego Convention Center Corporation. 🔬 With a focus on forging #partnerships, we're ready to engage with #biotech and #pharma companies to drive forward impactful advancements in biomedical research. At Myllia, we utilize #CRISPR screens with high-content read-outs to identify and validate mechanistic links between potential drug targets and disease-associated phenotypes. 🚀 Stay tuned for updates on Myllia's journey at #BIO2024 and reach out to Henrik Schmidt to discuss how #functional #genomics and #genetic #screening in primary cells can advance your #drug #discovery projects! Learn more here: www.myllia.com

Incredibly exciting paper published in Nature on the impact of genetic validation of drug targets on the success of the respective drugs: https://lnkd.in/edsE4pXd The paper estimates the probability of success for drug mechanisms with genetic support is 2.6 times greater than those without. Given the large costs associated with drug discovery and given the high attrition rates, genetic validation will have a huge impact! Congrats to Eric Vallabh Minikel, Matthew Nelson and the entire team! If you would like to obtain genetic support for your next drug discovery campaign, please reach out to Myllia Biotechnology to conceive a tailor-made CRISPR screen in your biological area of interest!

Congratulations to Alexandra POPA, Venu Thatikonda and the Boehringer Ingelheim team on their publication in Cell Reports - Cell Press, developing a pipeline to unravel associations between transcription factor activity and gene dependencies across tumour types. The CROP-Seq workflow used at Myllia Biotechnology enabled the validation of TEAD1-associated gene dependencies, and we are proud to be part of this insightful study. It is an example of one of the many ways in which #pooled #CRISPR #screens combined with single-cell RNA sequencing can support drug discovery programs. Read the full article here: https://lnkd.in/dhwq4NwB

Myllia Biotechnology co-founder and CeMM Principal Investigator Christoph Bock published a study entitled "JAK-STAT signaling maintains homeostasis in T cells and macrophages" in Nature Immunology. https://lnkd.in/dBUfhxsG In this study, a series of 12 mouse models were subjected to deep phenotyping, assessing both transcriptional profiles and chromatin accessibility in immune cells. In summary, this large-scale dataset and integrative analysis of JAK-STAT mutant and wild-type mice uncovered a crucial role of JAK-STAT signaling in immune cell homeostasis. Congrats to Nikolaus Fortelny, Matthias Farlik, Christoph Bock and all other co-authors!